Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function

NCT01331941 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01331941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01331941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
September 19, 2011
Completion date
Not reported
Enrollment
35 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, kidney disease, renal impairment